Extension Study to Evaluate the Long-term Outcomes of Subjects Following CLS-AX Administration for Age-related Macular Degeneration in the CLS-AX CLS1002-101 Study
Latest Information Update: 07 Mar 2024
At a glance
- Drugs Axitinib (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Clearside Biomedical
- 27 Apr 2023 Results presented in a Clearside Biomedical media release.
- 27 Apr 2023 According to a Clearside Biomedical media release, data from trials (OASIS, NCT04626128; Extension Study NCT05131646) presented in key poster presentations were delivered on the Company's suprachoroidal injection delivery platform at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting.
- 19 Apr 2023 According to a Clearside Biomedical media release, data from this study will be presented at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting taking place April 23-27, 2023, in New Orleans, LA.